MYCN and cancer: THZ1 has also been shown to be effective in MYCN-driven neuroblastoma and small cell lung cancer cells, where treatment showed preferential inhibition of superenhancer-driven genes including MYCN and other oncogenes, suggesting that CDK7 inhibition might be an interesting therapeutic strategy for transcription-addicted and MYC-driven cancers [28,29].